Immune Targeting Systems Ltd.

Altimmune UK Limited

Novartis Ag

Medeva Europe Limited

Seqirus UK Limited

Philip J. Sizer

Carlton B. Brown

Bertrand Georges

Dominique Bonnet

Philip J Sizer

Carlton B Brown

Carlton Bradley Brown

Bertrand V Georges

Bertrand Victor Gilbert Georges

Bernhard Roth

Bridget Kathleen Mapleson

Ian George Furminger

Anthony Colegate

Roger Williams

David Simpkin

Jane King-Haughey

Kevin Murphy

Gerard Chan

Arne Neumann

The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.

Antigen delivery vectors and constructs

The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.

Influenza antigen delivery vectors and constructs

Influenza hemagglutinin (HA) binds to aluminum salt adjuvants and cannot easily be directly assayed directly a single radial immunodiffusion (SRID) test. The invention modifies the SRID protocol for an adsorbed antigen by including a step in which antigen is desorbed prior to diffusion.

Assays for adsorbed influenza vaccines

Antigen and adjuvant components of an adjuvanted influenza vaccine are not mixed during manufacture, but are provided as separate components for extemporaneous mixing at the time of use, for example as a kit comprising (i) an antigen component, comprising an influenza virus antigen; and (ii) an adjuvant component, comprising an aluminium salt.

Influenza vaccines extemporaneously adsorbed to aluminium adjuvants

A method of removing bacterial endotoxin from a pharmaceutical process solution is disclosed. In one embodiment, the method comprises treating the solution with a surfactant effective to dissociate the endotoxin from a pharmaceutical drug or vaccine substance in the solution, and then filtering the solution through a molecular cut-off filter having a pore size effective to retain the pharmaceutical drug or vaccine substance but allow the dissociated bacterial endotoxin to pass therethrough.

Method of removing endotoxin from vaccines

Pharmaceutical compositions containing D.sub.2 O

Growing community of inventors

Helsby, United Kingdom

Philip J Sizer